Status:

COMPLETED

Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19)

Lead Sponsor:

Hospital Alemão Oswaldo Cruz

Collaborating Sponsors:

EMS S/A

Hospital do Coracao

Conditions:

COVID-19

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

In December 2019, a group of patients with pneumonia of unknown cause was identified in Wuhan, in the Hubei province, China. Despite the need of target specific therapeutic options for COVID-19, until...

Detailed Description

Pragmatic, double-blind, placebo-controlled randomized parallel-group, two-arm clinical trial (with allocation ratio 1:1), evaluating hydroxychloroquine (800 mg at 1st day, and 400 mg from day 2 to 7)...

Eligibility Criteria

Inclusion

  • It will be considered eligible those adults (equal to or greater than 18 years) seeking medical care with suspected or confirmed COVID-19, with time between symptoms and inclusion ≤ 07 days, presenting mild symptoms, without indication of hospitalization and at least 1 risk factor for complication:
  • \> 65 years;
  • Hypertension;
  • Diabetes mellitus;
  • Asthma;
  • COPD or other chronic lung diseases;
  • Smoking;
  • Immunosuppression;
  • Obesity (Defined as BMI equal to or greater than 30 Kg/m2).

Exclusion

  • Patients under 18 years old;
  • Hospitalization at the first medical care;
  • Positive test for influenza at the first medical care;
  • Known hypersensitivity to hydroxychloroquine / chloroquine;
  • Previous diagnosis of retinopathy or macular degeneration;
  • Previous diagnosis of Long QT-syndrome, history of sudden death in close family members (parents and siblings), decompensated heart failure, unstable coronary artery disease, use of anti-arrhythmic drugs or other drugs that can increase the hydroxychloroquine bioavailability or enhance its effect;
  • Evidence of known liver disease, reported by the patient;
  • Evidence of known chronic kidney disease, reported by the patient;
  • Patients with pancreatitis;
  • Baseline ECG with QTc interval ≥ 480ms;
  • Chronic use of hydroxychloroquine/chloroquine for other reasons;
  • Pregnancy.

Key Trial Info

Start Date :

May 12 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 28 2021

Estimated Enrollment :

1372 Patients enrolled

Trial Details

Trial ID

NCT04466540

Start Date

May 12 2020

End Date

September 28 2021

Last Update

March 7 2022

Active Locations (69)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 18 (69 locations)

1

Centro de Pesquisas Clínicas Dr. Marco Mota HCOR

Maceió, Alagoas, Brazil

2

Hospital Maternidade São Vicente de Paulo

Barbalha, Ceará, Brazil

3

Hospital Unimed Cariri

Juazeiro do Norte, Ceará, Brazil

4

Unimed Sul Capixaba

Cachoeiro de Itapemirim, Espírito Santo, Brazil